Announced Fri, 4 Sept · 12:46 IST

Trident Lifeline FY26 Annual Report: Revenue 129cr, PAT up 84%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.3%1-day move
₹272.95
prior close
₹300.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+6.3+5.5+6.1+8.9+10.3+11.3
Up moveDown movePending
AI summary

Trident Lifeline filed its FY2025-26 Annual Report ahead of the 13th AGM on September 26, 2026. Consolidated revenue grew 48% to Rs 129.0 crore, EBITDA rose 89% to Rs 28.1 crore with margin at 21.8% (up 470 bps), and PAT increased 84% to Rs 19.3 crore. 4-year revenue CAGR at 56%. The pharma exporter now operates across 46 countries with 1,091 registrations and 2,534 in pipeline, spanning 5 business verticals including injectables and nutraceuticals expected to contribute from FY27.

Likely market impact

Strong growth across revenue and profitability signals healthy demand and operating leverage. New injectables and nutraceutical verticals expected to add revenue from FY27.